Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years

This is an extended observation study of a RCT comparing the efficacy of romorozumab and denosumab in high-risk patients using long-term glucocorticoids. In the romosozumab arm, patients were shifted to denosumab after the first year. The denosumab arm of patients were continued on denosumab. This study aims to look at the bone mineral density changes in both groups of patients after 6 years.

Inclusion Criteria: \- patients who are continued on 6-monthly subcutaneous injection of DEN in either the ROMO or DEN arms after month 48; (2) those who are willing to have a repeat DXA assessment at the end of 6 years Exclusion Criteria: * patients who refuse to be maintained on denosumab after month 48 * patients who are maintained on other anti-osteoporotic drugs after month 48 * patients in whom prednisolone is planned to be tapered or discontinued after month 48.